Vascular endothelial growth factor (VEGF) has demonstrated to be central to the pathology of several ophthalmic diseases.1 Anti-VEGF therapy has dramatically improved the prognosis of many of these common vision-threatening retinal diseases. Click here to review current treatments of these diseases, with an emphasis on anti-VEGF therapy.
This supplement is provided by Regeneron Pharmaceuticals, Inc.
Sponsor
This supplement is provided by Regeneron Pharmaceuticals, Inc.
Vascular endothelial growth factor (VEGF) has demonstrated to be central to the pathology of several ophthalmic diseases.1 Anti-VEGF therapy has dramatically improved the prognosis of many of these common vision-threatening retinal diseases. Click here to review current treatments of these diseases, with an emphasis on anti-VEGF therapy.
Mitchell J. Goff, MD Retina Specialist Rocky Mountain Retinal Consultants Salt Lake City, UT
1. Apte RS, Chen DS, Ferrara N. VEGF in signaling and disease: beyond discovery and development. Cell. 2019;176(6):1248-1264.
EYL.20.06.0028 07/2020
Vascular endothelial growth factor (VEGF) has demonstrated to be central to the pathology of several ophthalmic diseases.1 Anti-VEGF therapy has dramatically improved the prognosis of many of these common vision-threatening retinal diseases. Click here to review current treatments of these diseases, with an emphasis on anti-VEGF therapy.
